Juliane Flor

Mrs. Juliane Flor

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JFJuliane Flor
Juliane Flor
ASAndresa Thomé Silveira
Andresa Thomé Silveira
IMIsabel Amaral Martins
Isabel Amaral Martins
LSLaura Bastos Otero Scherer
Laura Bastos Otero Scherer
FSFlávia Moraes Silva
Flávia Moraes Silva
Katya RigattoKatya Rigatto
Katya Rigatto
Objective: This scoping review aims to comprehensively map the existing literature on the mechanisms of action of Alamandine (ALA), a peptide within the renin–angiotensin system, and its effects across various physiological systems. Materials and Methods: Utilizing the Joanna Briggs Institute methodology, a thorough search of databases including PubMed, Embase, Scopus, and Web of Science was conducted up to 30 January 2025. The review focused on identifying studies that explore the biological and therapeutic roles of ALA in different contexts, incorporating in vivo, in vitro, and in silico research. Results: A total of 590 records were initially identified, with 25 meeting the eligibility criteria for inclusion in this review. China emerged as the leading contributor to the research in this area, with a significant focus on the cardiovascular system. The studies revealed that ALA exhibits a range of beneficial effects, including anti-inflammatory, vasodilatory, antifibrotic, and antiapoptotic actions. These effects are primarily mediated through the inhibition of the mitogen-activated protein kinase (MAPK) signaling pathway and modulation of the nitric oxide pathway. The review also highlighted AL’s potential in mitigating oxidative stress and its implications in treating cardiovascular diseases, fibrosis, and cancer. Conclusions: The findings suggest that ALA holds significant therapeutic potential, offering antihypertensive, anti-inflammatory, antifibrotic, and anticancer benefits without notable adverse effects, warranting further research to explore its full potential and mechanism of action.

21 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAndresa Thomé Silveira
Andresa Thomé Silveira
LFLucas Sagrillo Fagundes
Lucas Sagrillo Fagundes
JFJuliane Flor
Juliane Flor
IMIsabel Amaral Martins
Isabel Amaral Martins
LSLaura Bastos Otero Scherer
Laura Bastos Otero Scherer
Katya RigattoKatya Rigatto
Katya Rigatto
Objective: We aimed to assess the expression and localization of renin-angiotensin system (RAS) receptors in lung tissue and the plasma concentration of related peptides in IPF patients. Materials and Methods: This case–control study involved 19 patients from southern Brazil undergoing lung resection or transplantation. Plasma levels of Angiotensin I, II, A, 1-7, Alamandine were measured via liquid chromatography–tandem mass spectrometry. Lung tissue expression and localization of angiotensin type 1 (AT1), Mas, and Mas-related G-protein-coupled receptor D (MrgD) receptors were evaluated using Western blot and immunohistochemistry. Clinical data and the 6-min walk test were analyzed to correlate receptor expression with lung function and oxygen dependence. Results: IPF patients showed reduced forced vital capacity (FVC) at 49 ± 13% and forced expiratory volume (FEV1) at 51 ± 14%, with a 60% increase in oxygen dependence. Plasma peptide concentrations were similar between the groups, except for Angiotensin I, which was significantly higher in the control group. In IPF lungs, AT1 and Mas receptors were expressed 2.31 and 2.13 times more, respectively, while MrgD expression was lower. Mas receptors were mostly found in bronchiole areas, whereas MrgD was predominant in the lung parenchyma. Conclusions: This study indicates that the RAS operates independently within tissue, in addition to its systemic functions, highlighting distinct differences between tissue and plasma RAS activities. The distinct roles of MrgD and Mas receptors in lung structure and function could be pivotal for new therapies, potentially leading to more effective IPF treatments.

24 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JFJuliane Flor
Juliane Flor
ASAndresa Thomé Silveira
Andresa Thomé Silveira
IMIsabel Amaral Martins
Isabel Amaral Martins
LSLaura Bastos Otero Scherer
Laura Bastos Otero Scherer
FSFlávia Moraes Silva
Flávia Moraes Silva
Katya RigattoKatya Rigatto
Katya Rigatto
This scoping review aims to comprehensively map the existing literature on the mechanisms of action of Alamandine (ALA), a peptide within the renin-angiotensin system, and its effects across various physiological systems. Materials and Methods: Utilizing the Joanna Briggs Institute methodology, a thorough search of databases including PubMed, Embase, Scopus, and Web of Science was conducted up to January 30, 2025. The review focused on identifying studies that explore the biological and therapeutic roles of ALA in different contexts, incorporating in vivo, in vitro, and in silico research. Results: A total of 590 records were initially identified, with 26 meeting the eligibility criteria for inclusion in this review. China emerged as the leading contributor to research in this area, with a significant focus on the cardiovascular system. The studies revealed that ALA exhibits a range of beneficial effects, including anti-inflammatory, vasodilatory, antifibrotic, and antiapoptotic actions. These effects are primarily mediated through the inhibition of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway and modulation of the nitric oxide pathway. The review also highlighted ALA's potential in mitigating oxidative stress and its implications in treating cardiovascular diseases, fibrosis, and cancer. Conclusions: The findings suggest that ALA holds significant therapeutic potential, offering antihypertensive, anti-inflammatory, antifibrotic, and anticancer benefits without notable adverse effects. This underscores its promise as a therapeutic agent in various clinical settings, warranting further research to explore its full potential and mechanism of action.

20 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAndresa Thomé Silveira
Andresa Thomé Silveira
LFLucas Sagrillo Fagundes
Lucas Sagrillo Fagundes
JFJuliane Flor
Juliane Flor
IMIsabel Amaral Martins
Isabel Amaral Martins
LSLaura Bastos Otero Scherer
Laura Bastos Otero Scherer
Katya RigattoKatya Rigatto
Katya Rigatto
Objective: To assess the expression and localization of RAS receptors in lung tissue and the plasma concentration of related peptides in IPF patients. Materials and Methods: This case-control study involved 19 patients from southern Brazil undergoing lung resection or transplantation. Plasma levels of Angiotensin I, II, A, 1-7, Alamandine were measured via liquid chromatography-tandem mass spectrometry. Lung tissue expression and localization of angiotensin type 1 (AT1), Mas, and Mas-related G-protein-coupled receptor D (MrgD) receptors were evaluated using Western blot and immunohistochemistry. Clinical data and the 6-minute walk test were analyzed to correlate receptor expression with lung function and oxygen dependence. Results: IPF patients showed reduced forced vital capacity (FVC) at 49±13% and forced expiratory volume (FEV1) at 51±14%, with a 60% increase in oxygen dependence. Plasma peptide concentrations were similar between the group, with the exception on Angiotensin I, which was significantly higher in the control group. In IPF lungs, AT1 and Mas receptors were expressed 2.31 and 2.13 times more, respectively, while MrgD expression was lower. Mas receptors were mostly found in alveolar areas, whereas MrgD was predominant in the lung parenchyma. Conclusions: This study indicates that the RAS operates independently within tissue, in addition to its systemic functions, highlighting distinct differences between tissue and plasma RAS activities. The distinct roles of MrgD and Mas receptors in lung structure and function could be pivotal for new therapies, potentially leading to more effective IPF treatments.

1 January 2020 in Motriz Revista de Educação Física
Verified
Journal Article
Open access
PDF file
KLKelly Mônica Marinho e Lima
Kelly Mônica Marinho e Lima
JFJuliane Flor
Juliane Flor
RBRafael Inácio Barbosa
Rafael Inácio Barbosa
AMAlexandre Márcio Marcolino
Alexandre Márcio Marcolino
MAMarcela Gomes de Almeida
Marcela Gomes de Almeida
HKHeloyse Uliam Kuriki
Heloyse Uliam Kuriki
Aims: The purpose of our study was to compare the hip and knee muscle activity before and after a hip abduction exercise program in women with patellofemoral pain (PFP). Methods: Eleven women with PFP were included in our pre/post design study. Participants were assessed before and after 12-week hip abduction exercise program. All participants performed 6 stair climbing repetitions, 3 sets of rope jumps over 30 s and 5 sets of 8 squats to standardize the physical activity level before data collection. We recorded the electromyographic activity from gluteus medius, vastus medialis (VM) and vastus lateralis (VL) for double-legged squat with and without isometric hip abduction. Additionally, participants were asked to perform a step-down test to assess objective function (maximum number of repetitions over 30 s) and completed a clinical evaluation. Results: Longer duration of VM (Mean difference [95% CI]) = -0.97 [-1.48; -0.46], ES [effect size] = 0.66) and VL (-0.81 [-1.35; -0.27], ES = 0.54) were found after the hip abduction exercise program only for free squat. The participants also performed higher number of step-down repetitions (-3.54 [-5.84; -1.25], ES = 1.03) after the hip abduction exercise program and showed improvement in pain reports. Conclusion: A 12-week hip abduction exercise program changed the quadriceps muscle activation pattern and improved pain and objective function of women with PFP. The exercises promoted a longer VM and VL activation duration. Additionally, they promoted a clinical improvement in the patients with PFP.